So careless of the single trial

Evidence-Based Mental Health

Volumn 11, Issue 3, 2008, Pages 65-66

  Tyrer, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EVIDENCE BASED MEDICINE; HUMAN; LITERATURE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 49649097523     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebmh.11.3.65-a     Document Type: Short Survey

References (5)

1. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Categories of evidence relevant to specific causal relationships and treatments. Rockville, MD: Agency for Health Care Policy and Research Publications, 1992.
2. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
3. Lieberman JA, Stroup S, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
4. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
5. Davies LM, Lewis S, Jones PB, et al, on behalf of the CUtLASS team. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007;191:14-22. (Pubitemid 47035176)